| Sep 13 |
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
|
| Sep 9 |
Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
|
| Aug 25 |
Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?
|
| Jul 23 |
Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment
|
| Jul 22 |
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
|
| Jul 16 |
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
|
| Jul 11 |
Nuvalent names Henry Pelish as chief scientific officer
|
| Jul 11 |
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
|
| Jun 24 |
Nuvalent: Making Precise Progress In Its Oncology Pipeline
|
| Jun 14 |
Nuvalent: NVL-655 Could Bring Blockbuster Potential
|
